WHO ICTRP trial
A phase II study of brentuximab vedotin in patients with lymphomas
KCT0009738 · Clinical Research Information Service (CRIS) · Not Recruiting
Key facts
| Trial ID | KCT0009738 |
|---|---|
| Public title | A phase II study of brentuximab vedotin in patients with lymphomas |
| Scientific title | A phase II study of brentuximab vedotin in patients with relapsed or refractory EBV- and CD30-positive lymphomas |
| Primary sponsor | Seoul National University Hospital |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Not Recruiting |
| Study type | Interventional Study |
| Phase | Phase2 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : brentuximab vedotin will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg. Dosing is based on subjects’ weight according to the… |
| Registration date | Aug 30, 2024 |
| Target size | 25 |
| Registry page | cris.nih.go.kr |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: